Our current study identified the clinical usefulness of MGMT, NUPR1, NDRG2, and GLI1 promoter methylation as promising, predictive, and/or prognostic molecular biomarkers as well as potential epigenetic therapeutic targets in GBM patients. This evidence concerns the gene NUPR1 and glioblastoma.